AVITA Medical, Inc. (ASX:AVH)
Australia
· Delayed Price · Currency is AUD | Market Cap | 300.64M |
| Revenue (ttm) | 114.90M |
| Net Income (ttm) | -91.47M |
| Shares Out | n/a |
| EPS (ttm) | -3.51 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 318,576 |
| Average Volume | 319,368 |
| Open | 2.330 |
| Previous Close | 2.300 |
| Day's Range | 2.285 - 2.340 |
| 52-Week Range | 2.285 - 4.520 |
| Beta | 1.74 |
| RSI | 30.80 |
| Earnings Date | May 8, 2025 |
About AVITA Medical
AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company’s lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting devi... [Read more]
Financial Performance
In 2024, AVITA Medical's revenue was $64.25 million, an increase of 28.14% compared to the previous year's $50.14 million. Losses were -$61.85 million, 74.8% more than in 2023.
Financial numbers in USD Financial StatementsNews
AVITA Medical: Near-Perfect Execution Needed To Navigate Through Balance Sheet Challenges
AVITA Medical (RCEL) Sees Revenue Surge with Product Launches
AVITA Medical (RCEL) Sees Revenue Surge with Product Launches
AVITA Medical outlines $3.5B US market opportunity with expanded product portfolio and 2025 revenue guidance
AVITA Medical, Inc. (RCEL) Q1 2025 Earnings Call Transcript
AVITA Medical, Inc. 2025 Q1 - Results - Earnings Call Presentation
AVITA Medical Reports First Quarter 2025 Financial Results
VALENCIA, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today reported fina...
AVITA Medical to Announce First Quarter 2025 Financial Results
VALENCIA, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound company delivering transformative solutions, today announced that i...
AVITA Medical to Present Breakthrough Clinical Data in Burn and Wound Care at ABA 2025
VALENCIA, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering a portfolio of transformative solutions, to...
AVITA Medical Launches Cohealyx, Supporting Healing and Unlocking New Market Opportunity
VALENCIA, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced t...
AVITA Medical signs manufacturing deal with Stedical Scientific for PermeaDerm
AVITA Medical has signed a new contract manufacturing agreement for PermeaDerm biosynthetic wound matrix with Stedical Scientific.
AVITA Medical Announces Exclusive Manufacturing and Distribution Agreements with Stedical Scientific
AVITA Medical announces new manufacturing agreement and amended distribution agreement with Stedical Scientific to further commercialization of PermeaDerm.
AVITA Medical to Present at TD Cowen's 45ᵗʰ Annual Health Care Conference
VALENCIA, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL , ASX: AVH)), a leading therapeutic acute wound care company delivering transformative solutions, today announced ...
AVITA Medical to Present at TD Cowen's 45ᵗʰ Annual Health Care Conference
AVITA Medical announced that Jim Corbett, CEO, will present at TD Cowen's 45th Annual Health Care Conference on March 4, 2025, at 11:50 a.m. Eastern Time.
Insider Buying: Robert Mcnamara Acquires 10,000 Shares of AVITA Medical Inc (RCEL)
Insider Buying: Robert Mcnamara Acquires 10,000 Shares of AVITA Medical Inc (RCEL)
After Sales Rebound In January, AVITA Is Set Up For A Monster Year
After Sales Rebound In January, AVITA Is Set Up For A Monster Year
AVITA Medical Inc (AVHHL) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
AVITA Medical Inc (AVHHL) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Product Launches
Q4 2024 AVITA Medical Inc Earnings Call Transcript
Q4 2024 AVITA Medical Inc Earnings Call Transcript
AVITA Medical to Host Investor Webinar Briefing
AVITA Medical invites shareholders and prospective investors to attend its investor webinar briefing and presentation on February 18, 2025 at 2:00PM PT.
Avita Medical targets $3.5B TAM with expanded portfolio amid Cohealyx launch in 2025
AVITA Medical, Inc. (RCEL) Q4 2024 Earnings Call Transcript
AVITA Medical, Inc. 2024 Q4 - Results - Earnings Call Presentation
AVITA Medical Reports Fourth Quarter and Full Year 2024 Financial Results
VALENCIA, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today reported fin...